The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.

San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.

AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.

Biodexa Pharmaceuticals PLC has reported encouraging preliminary results from a Phase I clinical trial for MTX110.

Frontier Medicines recently closed an $80 million Series C funding round, with plans to advance its novel KRAS blocker, FMC-376.

J INTS BIO has announced that the Phase 1/2 clinical trial of its new oral 4th generation EGFR TKI, named "JIN-A02," for treating non-small cell lung cancer (NSCLC).

AceLink Therapeutics has reported positive preliminary findings for AL01211, an oral medication being developed to treat Fabry and Type 1 Gaucher diseases.

Cynata Therapeutics Limited has released initial data from its Phase 1 clinical trial of CYP-006TK for diabetic foot ulcers (DFU).

Kura Oncology has initiated its Phase 1 clinical trial, KOMET-008, which involves administering the menin inhibitor ziftomenib in tandem with gilteritinib.

Biora Therapeutics has achieved a significant milestone in its clinical trials for a novel drug-device combination, BT-600.

On February 16, 2024, a significant milestone in cancer treatment was achieved with the FDA's approval of the first-ever single-session cell therapy for solid tumors, marking an innovative step forward in the field.

RECCE® 327, when administered daily or every other day for two weeks, has proven to be both safe and well-tolerated.